Description: Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Home Page: www.metagenomi.co
5959 Horton Street
EmeryVille,
CA
94608
United States
Phone:
510 871 4880
Officers
| Name | Title |
|---|---|
| Dr. Brian Charles Thomas Ph.D. | Co-Founder, CEO & Chairman of the Board |
| Dr. Jian Irish M.B.A., Ph.D. | President, COO & Director |
| Dr. Sarah B. Noonberg M.D., Ph.D. | Chief Medical Officer |
| Dr. Joseph Knowles M.D. | Co-Founder & Member of Scientific Advisory Board |
| Ms. Pamela M. Wapnick M.B.A. | Chief Financial Officer |
| Mr. Simon Harnest M.Sc. | Chief Investment Officer & Senior VP of Investor Relations |
| Mr. Matthew L. Wein J.D. | Vice President of Corporate Legal, Compliance & Corporate Secretary |
| Dr. Alan Brooks Ph.D. | Senior Vice President of Preclinical |
| Dr. Christopher Brown | Head of Discovery |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5648 |
| Price-to-Sales TTM: | 2.6838 |
| IPO Date: | 2024-02-09 |
| Fiscal Year End: | September |
| Full Time Employees: | 236 |